Product pipeline and R&Dpositive · 5 filings
“The increase in facility-related and other expenses was primarily due to the increased costs of supporting a larger number of research and development personnel.”10-Q · Jul 29, 2026 ↗
Dyne Therapeutics, Inc.
DYN
Market read
Dyne Therapeutics, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.
Company-4.0% todayVolume comparison unavailable
Market group0 of 37 activeBiotechnology · unavailable
Disclosed network0 of 3 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- Interest expense rose to $8.8M for the six months ended June 30, 2026, attributed to the Loan Agreement with Hercules and vendor financing.
Invalidation: The isolated read changes if DYN's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.
Evidence that supports
No thresholded supportive filing evidence is available yet.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- Interest expense rose to $8.8M for the six months ended June 30, 2026, attributed to the Loan Agreement with Hercules and vendor financing.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods0
Price observations327
Usable filing statements109
Verified relationships9
Evidence supporting the case
- Product pipeline and R&D has repeated favorable evidence across 5 filings.
Evidence challenging the case
No qualifying adverse evidence was identified; that is not proof there is no downside.
Questions before a position
No credible peer-relative valuation comparison is available yet.
Longer-term price context
Price as of Sep 10, 2026
18.416m-7.9%12m+38.9%24m—
What management says matters
Persistent and emerging business drivers
Credit and interest ratesmixed · 4 filings
“Interest expense for the six months ended June 30, 2025 was less than $0.1 million due to our Loan Agreement with Hercules.”10-Q · Jul 29, 2026 ↗
Legal and regulatory exposurepositive · 4 filings
“We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management has devoted and will continue to be required to devote substantial time to new compliance initiatives and corporate governance practic…”10-Q · May 11, 2026 ↗
Supply chain and availabilitymixed · 2 filings
“For the full year 2026, we expect manufacturing costs to increase progressively each quarter as a result of long lead times to build supply and we project manufacturing costs for z-rostudirsen, z-basivarsen and other pipeline product candidates to represent 5…”10-Q · Jul 29, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales — · EV/sales —. Comparisons use only industry-matched filing peers.
Scenario scaffold
Fewer than 4 annual revenue periods; too little history to scaffold scenarios.
Price action
How the market is pricing the story
18.41-4.0% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for DYN. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for DYN. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind DYN
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
HTGCHercules Capital, Inc.lenderMay 11, 2026 ▾
“To date, we have principally raised capital through sales of equity securities and our borrowing under our Loan and Security Agreement, or the Loan Agreement, with Hercules Capital, Inc., or Hercules.”
ALNYAlnylam Pharmaceuticals, Inc.competitorMay 11, 2026 ▾
“We also expect to compete more generally with other companies developing alternative scientific and technological approaches to the treatment of muscle diseases, including other companies working to develop conjugates with oligonucleotides for extra-hepatic d…”
Depended on by
BMRNBioMarin Pharmaceutical Inc.competitorFeb 26, 2026 ▾
“In addition, BMN 351 could have potential competition from clinical product candidates for exon 51 skipping amenable DMD by Dyne Therapeutics, Inc.”
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
DYN is currently a Follower in the organic co-movement group Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for DYN; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.